Skip to main content
  • About Us
  • Image Credits
  • Contributor Info
  • RSS
  • Log In
  • Join
  • TwitterTwitter
  • E-Alerts
  • Visit StemJournal

Main menu

  • About
    • Image Credits
    • Contributor Info
    • E-Alerts
  • Chapters
    • Cellular and nuclear reprogramming
    • Ectoderm specification and differentiation
    • Endoderm specification and differentiation
    • Epigenetics
    • Genomics and proteomics
    • Germ cell and somatic stem cell biology in reproduction
    • Manufacturing
    • Mesoderm specification and differentiation
    • Niche biology, homing, and migration
    • Renewal
    • Stem cell immunology
    • Therapeutic prospects
    • Tissue engineering
  • Protocols
    • Ectoderm differentiation
    • Endoderm differentiation
    • Genome editing
    • Mesoderm differentiation
    • Pluripotent stem cells
    • PSC characterization
    • PSC genetic stability
    • Reprogramming
  • StemLabs
    • Stem Cell COREdinates
    • Core Facility Profiles
      • Boston Children's Hospital Human Neuron Core
      • Boston University Center for Regenerative Medicine iPSC Core
      • Columbia Stem Cell Initiative Stem Cell Core Facility
      • Harvard Stem Cell Institute iPS Core Facility
    • Stem Cell Protocols
    • Stem Cell Reagents
    • Other Resources
  • News & Profiles
    • Latest News
    • Stem Cell Institute Profiles
  • Journal Stream
  • Forum

    Search form

    You are here

    Home

    Biblio

    Author Title [ Type(Asc)] Year
    Filters: Author is Plütschow, Annette  [Clear All Filters]
    Journal Article
    Eichenauer DA, Bühnen I, Plütschow A, Kobe C, Dietlein M, Wendtner C-M, Thorspecken S, Topp MS, Mauser M, von Tresckow B, et al. Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Hematol Oncol. 2022.
    • PubMed
    • Google Scholar
    Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS, Ostermann H, Dierlamm J, Mohm J, Thiemer J, et al. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(2):223-234.
    • PubMed
    • Google Scholar
    Gillessen S, Plütschow A, Fuchs M, Markova J, Greil R, Topp MS, Meissner J, Zijlstra JM, Eichenauer DA, Bröckelmann PJ, et al. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). Lancet Haematol. 2021;8(4):e278-e288.
    • PubMed
    • Google Scholar

    Disclaimer | Privacy Policy | StemBook is published by IOS Press, Copyright © 2021
    Copyright 2013 by the Massachusetts General Hospital. Some sections copyright 2008–2009 by The President and Fellows of Harvard College.

    IOS Press logoHSCI logoNIH logoMIND logo


    Creative Commons License
    All content unless otherwise noted is licensed under a Creative Commons Attribution 3.0 Unported License